California-based Intersect ENT files for an initial public offering worth up to $80 million in support of its drug-eluting implants for chronic sinusitis.
Drug-eluting devices maker Intersect ENT hopes to raise as much as $80 million in a newly registered initial public offering, according to SEC documents filed this week.
News Well, Drug-Device Combinations, Funding Roundup, Initial Public Offering (IPO), Otolaryngology/Ear, Nose & Throat (ENT)
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1jdTblY
Cap comentari:
Publica un comentari a l'entrada